Please use this identifier to cite or link to this item:
|Title:||Magnesium supplementation: pharmacokinetics in cardiac surgery patients with normal renal function||Austin Authors:||Biesenbach, Peter;Mårtensson, Johan;Osawa, Eduardo;Eastwood, Glenn M ;Cutuli, Salvatore;Fairley, Jessica;Matalanis, George ;Bellomo, Rinaldo||Affiliation:||Department of Cardiac Surgery, Austin Health, Heidelberg, Melbourne, Australia
Department of Intensive Care, Austin Health, Heidelberg, Melbourne, Australia
School of Public Health and Preventive Medicine, Monash University, Prahran, Victoria, Australia
Perioperative Medicine and Intensive Care, Karolinska University Hospital, Solna, Sweden.
Intensive Care Unit, Warringal Private Hospital, Heidelberg, Victoria, Australia
Intensive Care Medicine, The University of Melbourne, Melbourne, Victoria, Australia
|Issue Date:||11-Jan-2018||metadata.dc.date:||2018||Publication information:||Journal of Critical Care 2018; 44: 419-423||Abstract:||Intravenous magnesium is routinely administered in intensive care units (ICU) to treat arrhythmias after cardiothoracic surgery. There are no data on the pharmacokinetics of continuous magnesium infusion therapy. To investigate the pharmacokinetics of continuous magnesium infusion, focusing on serum and urinary magnesium concentration, volume of distribution and half-life. We administered a 10 mmol bolus of magnesium-sulfate followed by a continuous infusion of 3 mmol/h for 12 h in twenty cardiac surgery patients. We obtained blood and urine samples prior to magnesium administration and after one, six, and 12 h. Median magnesium levels increased from 1.09 (IQR 1.00-1.23) mmol/L to 1.59 (1.45-1.76) mmol/L after 60 min (p < .001), followed by 1.53 (1.48-1.71) and 1.59 (1.48-1.76) mmol/L after 6 and 12 h. Urinary magnesium concentration increased from 9.2 (5.0-13.9) mmol/L to 17 (13.6-21.6) mmol/L after 60 min (p < .001). Cumulative urinary magnesium excretion was 28 mmol (60.9% of the dose given). The volume of distribution was 0.25 (0.22-0.30) L/kg. There were no episodes of severe hypermagnesemia (≥3 mmol/L). Combined bolus and continuous magnesium infusion therapy leads to a significant and stable increase in magnesium serum concentration despite increased renal excretion and redistribution.||URI:||http://ahro.austin.org.au/austinjspui/handle/1/17051||DOI:||10.1016/j.jcrc.2018.01.011||ORCID:||0000-0002-1650-8939
|PubMed URL:||29353118||PubMed URL:||https://pubmed.ncbi.nlm.nih.gov/29353118||Type:||Journal Article|
|Appears in Collections:||Journal articles|
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.